SUNNYVALE, Calif.—Ceribell, Inc. (NASDAQ:CBLL) director Juliet Tammenoms Bakker recently made a notable acquisition of the company’s common stock. According to a recent SEC filing, Bakker purchased 237,234 shares on October 15, 2024, at a price of $17 per share, amounting to a total transaction value of approximately $4.03 million.
The transaction was conducted indirectly through Longitude Venture Partners IV, L.P., a firm where Bakker holds a significant role. Following this purchase, Bakker’s total indirect ownership in Ceribell stands at 2,475,110 shares.
This purchase comes shortly after an automatic conversion of 2,140,600 shares of Series C-1 Preferred Stock into common stock, which occurred in conjunction with Ceribell’s initial public offering on October 15, 2024. The conversion was executed without any additional cost, as stated in the filing.
Juliet Tammenoms Bakker, who serves as a member of Ceribell’s board of directors, is a managing member of Longitude Capital Partners IV, LLC, which holds voting and investment power over the shares. The filing notes that Bakker disclaims beneficial ownership of these securities except to the extent of her pecuniary interest.
Ceribell, Inc., based in Sunnyvale, California, specializes in electromedical and electrotherapeutic apparatus, and its recent IPO has drawn attention from investors and market analysts.
InvestingPro Insights
Ceribell’s recent IPO and the significant stock acquisition by director Juliet Tammenoms Bakker have brought the company into the spotlight. To provide a more comprehensive view of Ceribell’s financial position, let’s examine some key metrics from InvestingPro.
As of the latest data, Ceribell boasts a market capitalization of $868.5 million, reflecting investor confidence in the company’s potential. The company’s revenue growth is particularly noteworthy, with a robust 45.07% increase in quarterly revenue as of Q2 2024. This strong top-line growth aligns with the recent insider purchase and could be indicative of positive business momentum.
However, it’s important to note that Ceribell is currently operating at a loss, with an operating income of -$32.43 million over the last twelve months. This is reflected in the company’s negative P/E ratio of -27.42, suggesting that profitability remains a challenge for the medical device maker.
InvestingPro Tips highlight that Ceribell operates with a moderate level of debt and its liquid assets exceed short-term obligations. These factors could provide the company with financial flexibility as it seeks to capitalize on its recent growth and navigate the path to profitability.
Investors should also be aware that Ceribell is trading near its 52-week high, with its current price at 97.58% of the peak. This could indicate strong market sentiment following the IPO but also suggests that the stock might be fully valued at current levels.
For those interested in a deeper analysis, InvestingPro offers 7 additional tips for Ceribell, providing a more comprehensive understanding of the company’s financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
